Mercy Gilbert Medical Center

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease5 trials
• Atrial fibrillation3 trials
• Heart failure2 trials
• Obesity2 trials
• Stroke2 trials
• Familial hypercholesterolaemia1 trial
• Peripheral artery disease1 trial
• Postural tachycardia syndrome (POTS)1 trial

Phase

• Phase 39 trials
• Phase 21 trial
• Phase 41 trial

Status

• Completed6 trials
• Active, not recruiting4 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals3 trials
• Janssen Research & Development, LLC2 trials
• Novo Nordisk A/S2 trials
• American Heart Association1 trial
• Boehringer Ingelheim1 trial
• and 4 more

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· Phase 3· Eli Lilly and Company· Source

  Contact: Georges Nseir (principal investigator)

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

  NCT04562532· Shanghai MicroPort Medical (Group) Co., Ltd.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Heart failure1 recruiting
• Peripheral artery disease1 recruiting

Closed trials

• Completed

  Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

  NCT06593600· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  POLARx Post Approval Study (POLARx PAS)

  NCT06170606· Boston Scientific Corporation· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

  NCT05130268· Phase 4· American Heart Association· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source